Medlab Clinical Limited (MDC) 2022年年度报告「ASX」.pdf

1、Copyright Medlab Clinical Ltd 2022MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2022ASX:MDCCONTENTSChai rmans Letter4 CEO Report5 Di rectors Report13 Audi tors I ndependence Decl arati on25 Fi nanci al Statements26 Di rectors Decl arati on64 I ndependent Audi tor

2、s Report65 Sharehol der I nformati on68 Corporate Di rectory704CHAI RMANS LETTER Dear Sharehol ders I t i s my pl easure to present Medl ab Cl i ni cal Li mi teds 2022 Annual Report.The past year has been a busy and chal l engi ng year.The i mpacts of COVI D have certai nl y been fel t wi th manufac

3、turi ng and suppl y chai n del ays but despi te that,the Company has conti nued to make si gni ficant progressi on i n 2 key areas:Progressi on of the NanaBi s program as we work towards a New Drug Appl i cati on wi th the FDA Busi ness devel opment and l i cenci ng opportuni ti es Duri ng the year,

4、the Board deci ded to l i cence i ts Austral i an Nutraceuti cal busi ness to PharmaCare Pty Ltd.I t was consi dered that the busi ness woul d conti nue to requi re a si gni ficant number of resources to operate,and thi s arrangement woul d al l ow management to focus on current research programs an

5、d other emergi ng partneri ng opportuni ti es.The Company has conti nued to strengthen i ts i ntel l ectual property over the l ast year wi th the granti ng of patents for the NanoCel l e technol ogy.The technol ogy i s vi tal to our research and potenti al commerci al opportuni ti es and i s now pr

6、otected for the next 15 years i n the Ameri cas,Oceani a,and Europe.NanoCel l e conti nues to attract i nterest from vari ous compani es(mostl y i n the North Hemi sphere)whi ch i s why the Board took the posi ti on to progress towards a dual l i sti ng wi th the NASDAQ.A dual l i sti ng wi l l hel